Nektar Therapeutics NKTR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:43 PM EST
22.28quote price arrow down-0.03 (-0.13%)
Volume
11,186
Close
22.31quote price arrow down-0.07 (-0.31%)
Volume
1,275,389
52 week range
13.63 - 26.75

...

Loading . . .

KEY STATS

  • Open22.36
  • Day High22.49
  • Day Low20.84
  • Prev Close22.38
  • 52 Week High26.75
  • 52 Week High Date02/17/21
  • 52 Week Low13.63
  • 52 Week Low Date03/16/20
  • Market Cap4.064B
  • Shares Out182.18M
  • 10 Day Average Volume1.33M
  • Dividend-
  • Dividend Yield-
  • Beta1.59
  • 1 Year % Change10.72

RATIOS/PROFITABILITY

  • EPS (TTM)-2.49
  • P/E (TTM)-8.96
  • Fwd P/E (NTM)-7.60
  • EBITDA (MRQ)-365.729M
  • ROE (MRQ)-35.80%
  • Revenue (MRQ)152.92M
  • Gross Margin (MRQ)87.26%
  • Net Margin (MRQ)-290.65%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Nektar Therapeutics News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new...
Robert Chess
Chairman
Howard Robin
Chief Executive Officer
Gilbert Labrucherie J.D.
Chief Financial Officer
Address
455 Mission Bay Blvd S
San Francisco, CA
94158-2158
United States